Sökning: WFRF:(van Vollenhoven R.) > A framework for rem...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04936naa a2200949 4500 | |
001 | oai:prod.swepub.kib.ki.se:135295823 | |
003 | SwePub | |
008 | 240825s2017 | |||||||||||000 ||eng| | |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1352958232 URI |
024 | 7 | a https://doi.org/10.1136/annrheumdis-2016-2095192 DOI |
040 | a (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a van Vollenhoven, Ru Karolinska Institutet4 aut |
245 | 1 0 | a A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS) |
264 | c 2016-11-24 | |
264 | 1 | b BMJ,c 2017 |
520 | a Treat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission will be worded as follows: remission in SLE is a durable state characterised by …………………. (reference to symptoms, signs, routine labs).2. For defining remission, a validated index must be used, for example, clinical systemic lupus erythematosus disease activity index (SLEDAI)=0, British Isles lupus assessment group (BILAG) 2004 D/E only, clinical European consensus lupus outcome measure (ECLAM)=0; with routine laboratory assessments included, and supplemented with physician's global assessment.3. Distinction is made between remission off and on therapy: remission off therapy requires the patient to be on no other treatment for SLE than maintenance antimalarials; and remission on therapy allows patients to be on stable maintenance antimalarials, low-dose corticosteroids (prednisone ≤5 mg/day), maintenance immunosuppressives and/or maintenance biologics.The task force also agreed that the most appropriate outcomes (dependent variables) for testing the prognostic value (construct validity) of potential remission definitions are: death, damage, flares and measures of health-related quality of life.ConclusionsThe work of this international task force provides a framework for testing different definitions of remission against long-term outcomes. | |
700 | 1 | a Voskuyl, A4 aut |
700 | 1 | a Bertsias, G4 aut |
700 | 1 | a Aranow, C4 aut |
700 | 1 | a Aringer, M4 aut |
700 | 1 | a Arnaud, L4 aut |
700 | 1 | a Askanase, A4 aut |
700 | 1 | a Balazova, P4 aut |
700 | 1 | a Bonfa, E4 aut |
700 | 1 | a Bootsma, H4 aut |
700 | 1 | a Boumpas, D4 aut |
700 | 1 | a Bruce, I4 aut |
700 | 1 | a Cervera, R4 aut |
700 | 1 | a Clarke, A4 aut |
700 | 1 | a Coney, C4 aut |
700 | 1 | a Costedoat-Chalumeau, N4 aut |
700 | 1 | a Czirjak, L4 aut |
700 | 1 | a Derksen, R4 aut |
700 | 1 | a Doria, A4 aut |
700 | 1 | a Dorner, T4 aut |
700 | 1 | a Fischer-Betz, R4 aut |
700 | 1 | a Fritsch-Stork, R4 aut |
700 | 1 | a Gordon, C4 aut |
700 | 1 | a Graninger, W4 aut |
700 | 1 | a Gyori, N4 aut |
700 | 1 | a Houssiau, F4 aut |
700 | 1 | a Isenberg, D4 aut |
700 | 1 | a Jacobsen, S4 aut |
700 | 1 | a Jayne, D4 aut |
700 | 1 | a Kuhn, A4 aut |
700 | 1 | a Le Guern, V4 aut |
700 | 1 | a Lerstrom, K4 aut |
700 | 1 | a Levy, R4 aut |
700 | 1 | a Machado-Ribeiro, F4 aut |
700 | 1 | a Mariette, X4 aut |
700 | 1 | a Missaykeh, J4 aut |
700 | 1 | a Morand, E4 aut |
700 | 1 | a Mosca, M4 aut |
700 | 1 | a Inanc, M4 aut |
700 | 1 | a Navarra, S4 aut |
700 | 1 | a Neumann, I4 aut |
700 | 1 | a Olesinska, M4 aut |
700 | 1 | a Petri, M4 aut |
700 | 1 | a Rahman, A4 aut |
700 | 1 | a Rekvig, OP4 aut |
700 | 1 | a Rovensky, J4 aut |
700 | 1 | a Shoenfeld, Y4 aut |
700 | 1 | a Smolen, J4 aut |
700 | 1 | a Tincani, A4 aut |
700 | 1 | a Urowitz, M4 aut |
700 | 1 | a van Leeuw, B4 aut |
700 | 1 | a Vasconcelos, C4 aut |
700 | 1 | a Voss, A4 aut |
700 | 1 | a Werth, VP4 aut |
700 | 1 | a Zakharova, H4 aut |
700 | 1 | a Zoma, A4 aut |
700 | 1 | a Schneider, M4 aut |
700 | 1 | a Ward, M4 aut |
710 | 2 | a Karolinska Institutet4 org |
773 | 0 | t Annals of the rheumatic diseasesd : BMJg 76:3, s. 554-561q 76:3<554-561x 1468-2060x 0003-4967 |
856 | 4 | u http://diposit.ub.edu/dspace/bitstream/2445/123199/1/678610.pdf |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:135295823 |
856 | 4 8 | u https://doi.org/10.1136/annrheumdis-2016-209519 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.